Gaucher disease is the most common inherited lysosomal storage disorder;^[1] it represents a potentially serious health problem.^[2] Cerezyme^® (imiglucerase for injection) is enzyme replacement therapy for Type 1 Gaucher disease.^[5] It is the first preparation of glucocerebrosidase, the enzyme deficient in this disorder, produced using recombinant DNA technology. Cerezyme therapy is clinically proven to be safe and effective in relieving many of the signs and symptoms of Type 1 Gaucher disease.^[5] Please see important safety information below.

	Gaucher Disease Information Learn more about the genetic inheritance pattern of Gaucher disease, disease progression, and the diagnostic challenges associated with the disease.

Enhance recognition of diverse symptoms Learn more about the signs and symptoms with our interactive symptom tool for Gaucher disease.		Facilitate Diagnosis Learn more about diagnosing Gaucher disease, including a 2003 New England Journal of Medicine diagnostic case study of a nine year old girl.

Important Safety Information

Adverse reactions related to Cerezyme® (imiglucerase for injection) administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, vomiting, abdominal pain, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site of venipuncture. Symptoms suggestive of hypersensitivity include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension. Approximately 15% of patients have developed IgG antibodies; periodic monitoring is suggested. Side effects should be reported promptly to Genzyme Medical Information at 800-745-4447, option 2. To learn more, please see full product information (PDF), or contact Genzyme at 1-800-745-4447.

References

1. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160:2835-2843.

2. NIH Technology Assessment Panel on Gaucher Disease. Gaucher disease: current issues in diagnosis and treatment. JAMA. 1996;275:548-553.

3. Beutler E, Grabowski GA. Gaucher disease. In:Scriber CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease, 7^th ed. New York, NY: McGraw-Hill; 1995;2:2641-2661.

4. Grabowski G. Gaucher disease: enzymology, genetics, and treatment. In: Harris H, Hirshchorn K, eds. Advances in Human Genetics. New York, NY: Plenum Press; 1993;21:377-441.

5. Prescribing Information for Cerezyme® (imiglucerase for injection).